Lexeo Therapeutics, Inc. Common Stock (LXEO) ownership: Top institutional holder: VANGUARD GROUP INC ($38.67M). Insider activity: Net Seller (0 buys, 17 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| VANGUARD GROUP INC | 3894310.00 | $38.67M | 2025-12-31 |
| Paradigm Biocapital Advisors LP | 6184134.00 | $35.50M | 2026-03-31 |
| BlackRock, Inc. | 5110871.00 | $29.34M | 2026-03-31 |
| Affinity Asset Advisors, LLC | 5050211.00 | $28.99M | 2026-03-31 |
| RA CAPITAL MANAGEMENT, L.P. | 5000000.00 | $28.70M | 2026-03-31 |
| JANUS HENDERSON GROUP PLC | 4976429.00 | $28.51M | 2026-03-31 |
| Vestal Point Capital, LP | 4475000.00 | $25.69M | 2026-03-31 |
| Frazier Life Sciences Management, L.P. | 4424725.00 | $25.40M | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-05-18 | |
| Sell | null | 2026-05-18 | |
| Sell | null | 2026-04-28 | |
| Sell | null | 2026-04-06 | |
| Sell | null | 2026-03-13 | |
| Sell | null | 2026-03-13 | |
| Sell | null | 2026-02-18 | |
| Sell | null | 2026-02-18 |
Back to LXEO overview · LXEO earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.